Tango Therapeutics Q2 net loss widens to $55.3 million; G&A expenses climb 99% to $22.6 million

• Tango Therapeutics posted a Q2 net loss of $55.3 million, widening from $38.9 million a year earlier; loss per share was $0.37.
• R&D expenses rose to $37.2 million from $32.8 million, driven by higher spend on vopimetostat and TNG456 programs.
• G&A expenses climbed to $22.6 million from $11.3 million, on higher personnel-related costs including share-based compensation.
• Cash, cash equivalents and marketable securities totaled $1.0 billion at June 30, 2026; collaboration revenue was no revenue versus $3.2 million.
• Tango cited 92% objective response rate for vopimetostat with daraxonrasib in MTAP-deleted RAS-mutant pancreatic cancer, targeting Phase 3 design finalization in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807455) on August 11, 2026, and is solely responsible for the information contained therein.